Released May 7, 2015, after the close
10-Q filed May 7, 2015, 37 days after period end · 0001144204-15-028431
Q1 2015 · 10-Q
Revenue$1.69M$1.69M −74.7% vs Q1 2014no prior Q4 2014 on file
Net Income-$5.97M-$5.97M N/M vs Q1 2014N/M vs Q4 2014
EPS Diluted-$0.06-$0.06 N/M vs Q1 2014no prior Q4 2014 on file
Gross Profit$1,410,000−57.4%
Operating Income-$5,384,000N/M
Operating Cash Flow-$6,421,000N/M
Free Cash Flowderived-$6,520,000N/M
Margins · derived
Gross margin83.3%+33.9 pt vs Q1 2014
Operating margin-318.2%−221.6 pt vs Q1 2014
Net margin-353.0%−243.3 pt vs Q1 2014
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2015 | Q1 2014 | Q1 2013 | Q1 2012 |
|---|---|---|---|---|
| Revenue | $1.69M | $6.70M | $3.57M | $3.86M |
| Net Income | -$5.97M | -$7.35M | -$4.32M | -$5.90M |
| EPS Diluted | -$0.06 | $0.08 | $0.05 | $0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR